We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
- Authors
Talpaz, Moshe; Kantarjian, Hagop; Kurzrock, Razelle; Trujillo, Jose M.; Gutterman, Jordan U.; Talpaz, M; Kantarjian, H; Kurzrock, R; Trujillo, J M; Gutterman, J U
- Abstract
<bold>Objectives: </bold>To evaluate the frequency and the course of complete cytogenetic responses in interferon-alpha (IFN-alpha)-treated patients with chronic myelogenous leukemia.<bold>Design: </bold>Two prospective trials in consecutive patients.<bold>Setting: </bold>A major tertiary cancer center.<bold>Patients: </bold>Ninety-six consecutive patients with chronic myelogenous leukemia with disease duration of less than 1 year.<bold>Intervention: </bold>Patients received partially pure IFN-alpha intramuscularly, from 3 to 9 million U/d (51 patients) or recombinant IFN-alpha 2a (Roferon, Hoffmann-LaRoche, Inc., Nutley, New Jersey), 5 million U/m2 body surface area daily (45 patients).<bold>Measurements: </bold>Hematologic and cytogenetic tests were administered.<bold>Main Results: </bold>Seventy of the patients (73%) achieved hematologic remission (95% CI, 63% to 81%), and 18 (19%) had complete suppression of the Philadelphia chromosome on at least one cytogenetic test. A complete cytogenetic response was induced in 7 of 51 or 14% (CI, 6% to 26%) of the patients treated with the partially pure IFN-alpha and in 11 of 45 or 24% (CI, 13% to 40%) of the patients treated with recombinant IFN-alpha 2a. The difference in complete cytogenetic response between the two groups was 10.7% (CI, - 5% to 26%; P greater than 0.2). Eleven patients had durable, ongoing, complete cytogenetic responses from 6 to more than 45 months (median, more than 30 months).<bold>Conclusion: </bold>This study was the first to show sustained, complete cytogenetic responses in a subset of patients with chronic myelogenous leukemia treated with single-agent therapy. The nature of this remission, that is, whether it depends on continuous therapy, requires further study.
- Subjects
LEUKEMIA treatment; MYELOID leukemia; INTERFERONS; THERAPEUTIC use of interferons; THERAPEUTIC use of proteins; COMPARATIVE studies; KARYOTYPES; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; RECOMBINANT proteins; RESEARCH; EVALUATION research; CHRONIC myeloid leukemia; DISEASE remission
- Publication
Annals of Internal Medicine, 1991, Vol 114, Issue 7, p532
- ISSN
0003-4819
- Publication type
journal article
- DOI
10.7326/0003-4819-114-7-532